Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate

by Vandana Singh, Benzinga Editor

June 21, 2021 11:35 AM | 1 min read |

Arrowhead Pharmaceuticals Inc ARWR and Horizon Therapeutics plc HZNP have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout.
Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals’ ARO-XDH, an investigational RNAi therapy.
The deal includes $660 million in downstream milestones and potential royalties in the low- to mid-teens.
Horizon will handle clinical development and worldwide commercialization, with Arrowhead responsible for preclinical development.
Price Action: ARWR shares are up 4.13% at $89.18, and HZNP stock is up 0.17% at $94.77 during the market trading session on the last check Monday.

Posted In: Biotech News Health Care Contracts General Briefs Gout

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.